Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024

Full Year 2023            Full Year 2023             Outlook 2024              "Sobi's strategic portfolio grew strongly during the quarter and accounted for 40 per cent of revenue, underpinning our commitment to deliver new innovative medicines to people with rare diseases." - Guido Oelkers, President & CEO. Investors, analysts, and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at ...

Full Year 2023           

Outlook 2024            

"Sobi's strategic portfolio grew strongly during the quarter and accounted for 40 per cent of revenue, underpinning our commitment to deliver new innovative medicines to people with rare diseases." - Guido Oelkers, President & CEO.

Investors, analysts, and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at 14:00 CET, 13:00 pm GMT, and 8:00 am EDT.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

For other countries, please get details here

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 08 February 2024 at 8:00 CET.

Gerard Tobin, Head of Investor Relations

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/sobi-publishes-q4-2023-report-strong-revenue-performance-and-growth-into-2024-302057320.html